REFERENCES

1. Bloem BR, Okun MS, Klein C. Parkinson’s disease. Lancet 2021;397:2284-303.

2. Boertien JM, Murtomäki K, Pereira PAB, et al; PPNN Study Group. Fecal microbiome alterations in treatment-naive de novo Parkinson’s disease. NPJ Parkinsons Dis 2022;8:129.

3. Lancet. What next in Parkinson’s disease? Lancet 2024;403:219.

4. Chen H, Ding D, Wang J, et al. Parkinson’s disease research in a prospective cohort in China. Parkinsonism Relat Disord 2015;21:1200-4.

5. Leite Silva ABR, Gonçalves de Oliveira RW, Diógenes GP, et al. Premotor, nonmotor and motor symptoms of Parkinson’s disease: a new clinical state of the art. Ageing Res Rev 2023;84:101834.

6. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson’s disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-69.

7. Williams-Gray CH, Mason SL, Evans JR, et al. The CamPaIGN study of Parkinson’s disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013;84:1258-64.

8. Wallen ZD, Demirkan A, Twa G, et al. Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms. Nat Commun 2022;13:6958.

9. Ascherio A, Schwarzschild MA. The epidemiology of Parkinson’s disease: risk factors and prevention. Lancet Neurol 2016;15:1257-72.

10. Romano S, Savva GM, Bedarf JR, Charles IG, Hildebrand F, Narbad A. Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation. NPJ Parkinsons Dis 2021;7:27.

11. Boktor JC, Sharon G, Verhagen Metman LA, et al. Integrated multi-cohort analysis of the Parkinson’s disease gut metagenome. Mov Disord 2023;38:399-409.

12. Liang X, Fu Y, Cao WT, et al. Gut microbiome, cognitive function and brain structure: a multi-omics integration analysis. Transl Neurodegener 2022;11:49.

13. Ren T, Gao Y, Qiu Y, et al. Gut microbiota altered in mild cognitive impairment compared with normal cognition in sporadic Parkinson’s disease. Front Neurol 2020;11:137.

14. Bajaj JS, Hylemon PB, Ridlon JM, et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol Gastrointest Liver Physiol 2012;303:G675-85.

15. Cersosimo MG, Benarroch EE. Pathological correlates of gastrointestinal dysfunction in Parkinson’s disease. Neurobiol Dis 2012;46:559-64.

16. Tan AH, Lim SY, Lang AE. The microbiome-gut-brain axis in Parkinson disease - from basic research to the clinic. Nat Rev Neurol 2022;18:476-95.

17. Boehme M, Guzzetta KE, Bastiaanssen TFS, et al. Microbiota from young mice counteracts selective age-associated behavioral deficits. Nat Aging 2021;1:666-76.

18. Sun MF, Zhu YL, Zhou ZL, et al. Neuroprotective effects of fecal microbiota transplantation on MPTP-induced Parkinson’s disease mice: gut microbiota, glial reaction and TLR4/TNF-α signaling pathway. Brain Behav Immun 2018;70:48-60.

19. Sun H, Zhao F, Liu Y, et al. Probiotics synergized with conventional regimen in managing Parkinson’s disease. NPJ Parkinsons Dis 2022;8:62.

20. Chi H, Yao R, Sun C, et al. Blood neuroexosomal mitochondrial proteins predict Alzheimer disease in diabetes. Diabetes 2022;71:1313-23.

21. Li D, Liu CM, Luo R, Sadakane K, Lam TW. MEGAHIT: an ultra-fast single-node solution for large and complex metagenomics assembly via succinct de Bruijn graph. Bioinformatics 2015;31:1674-6.

22. Liu A, Ma T, Xu N, et al. Adjunctive probiotics alleviates asthmatic symptoms via modulating the gut microbiome and serum metabolome. Microbiol Spectr 2021;9:e0085921.

23. Caspi R, Billington R, Keseler IM, et al. The MetaCyc database of metabolic pathways and enzymes - a 2019 update. Nucleic Acids Res 2020;48:D445-53.

24. Magnúsdóttir S, Heinken A, Kutt L, et al. Generation of genome-scale metabolic reconstructions for 773 members of the human gut microbiota. Nat Biotechnol 2017;35:81-9.

25. Mallick H, Franzosa EA, Mclver LJ, et al. Predictive metabolomic profiling of microbial communities using amplicon or metagenomic sequences. Nat Commun 2019;10:3136.

26. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42.

27. Sen A, Tugcu B, Coskun C, Ekinci C, Nacaroglu SA. Effects of levodopa on retina in Parkinson disease. Eur J Ophthalmol 2014;24:114-9.

28. Dugger BN, Dickson DW. Pathology of neurodegenerative diseases. Cold Spring Harb Perspect Biol 2017;9:a028035.

29. Houser MC, Tansey MG. The gut-brain axis: is intestinal inflammation a silent driver of Parkinson’s disease pathogenesis? NPJ Parkinsons Dis 2017;3:3.

30. Liu J, Lv X, Ye T, et al. Microbiota-microglia crosstalk between Blautia producta and neuroinflammation of Parkinson’s disease: a bench-to-bedside translational approach. Brain Behav Immun 2024;117:270-82.

31. Qian Y, Yang X, Xu S, et al. Alteration of the fecal microbiota in Chinese patients with Parkinson’s disease. Brain Behav Immun 2018;70:194-202.

32. Aljumaah MR, Bhatia U, Roach J, Gunstad J, Azcarate Peril MA. The gut microbiome, mild cognitive impairment, and probiotics: a randomized clinical trial in middle-aged and older adults. Clin Nutr 2022;41:2565-76.

33. Bonham KS, Fahur Bottino G, McCann SH, et al; RESONANCE Consortium. Gut-resident microorganisms and their genes are associated with cognition and neuroanatomy in children. Sci Adv 2023;9:eadi0497.

34. Li N, Tan S, Wang Y, et al. Akkermansia muciniphila supplementation prevents cognitive impairment in sleep-deprived mice by modulating microglial engulfment of synapses. Gut Microbes 2023;15:2252764.

35. Zheng M, Ye H, Yang X, et al. Probiotic Clostridium butyricum ameliorates cognitive impairment in obesity via the microbiota-gut-brain axis. Brain Behav Immun 2024;115:565-87.

36. Cattaneo A, Cattane N, Galluzzi S, et al; INDIA-FBP Group. Association of brain amyloidosis with pro-inflammatory gut bacterial taxa and peripheral inflammation markers in cognitively impaired elderly. Neurobiol Aging 2017;49:60-8.

37. Kim N, Jeon SH, Ju IG, et al. Transplantation of gut microbiota derived from Alzheimer’s disease mouse model impairs memory function and neurogenesis in C57BL/6 mice. Brain Behav Immun 2021;98:357-65.

38. Song L, Sun Q, Zheng H, et al. Roseburia hominis alleviates neuroinflammation via short-chain fatty acids through histone deacetylase inhibition. Mol Nutr Food Res 2022;66:e2200164.

39. Chen SJ, Chen CC, Liao HY, et al. Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology 2022;98:e848-58.

40. Tan AH, Chong CW, Lim SY, et al. Gut microbial ecosystem in Parkinson disease: new clinicobiological insights from multi-omics. Ann Neurol 2021;89:546-59.

41. Nishiwaki H, Ito M, Hamaguchi T, et al. Short chain fatty acids-producing and mucin-degrading intestinal bacteria predict the progression of early Parkinson’s disease. NPJ Parkinsons Dis 2022;8:65.

42. Liu P, Wu L, Peng G, et al. Altered microbiomes distinguish Alzheimer’s disease from amnestic mild cognitive impairment and health in a Chinese cohort. Brain Behav Immun 2019;80:633-43.